David Beadle

David Beadle has over 20 years of work experience. In 2020, they were appointed as Director of Apobec Discovery Ltd. From 2018 to 2020, they served as Non Executive Director of Phico Therapeutics Ltd. From 2017 to 2018, they were CBO and Non-Executive Director of IMMUNE REGULATION LIMITED now REVOLO BIOTHERAPEUTICS. From 2008 to 2017, they were Non-executive director of Burgopak, and from 2008 to present, they are Founding Partner of Napa Capital Ltd. From 1999 to 2001, they were Managing Director Global & European Pharmaceutical Equity Research at UBS Investment Bank. Additionally, from 2001 to 2008, they were Non Executive Director of Bioenvision, a biotechnology company developing drugs for Leukaemia and Lymphoma, which was later acquired by Genzyme.

David Beadle attended the University of Birmingham from 1988 to 1991.